BG102710A - Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове - Google Patents

Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове

Info

Publication number
BG102710A
BG102710A BG102710A BG10271098A BG102710A BG 102710 A BG102710 A BG 102710A BG 102710 A BG102710 A BG 102710A BG 10271098 A BG10271098 A BG 10271098A BG 102710 A BG102710 A BG 102710A
Authority
BG
Bulgaria
Prior art keywords
hiv
chimerical
inhibitor
data
type
Prior art date
Application number
BG102710A
Other languages
English (en)
Inventor
Bethune Marie-Pierre De
Kurt Hertogs
Rudi Pauwels
Original Assignee
Virco N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco N.V. filed Critical Virco N.V.
Publication of BG102710A publication Critical patent/BG102710A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Методът осигурява фенотипна информация за индивидуални, заразени с НIV пациенти в широки мащаби икономично и бързо. Той е приложим към всички наличнив момента химиотерапевтични режими и може да бъдееднакво приложим и при бъдещи такива режими. Методът включва трансфекция на клетъчна линия, податлива на инфекция с НIV, с последователност, за предпочитане тази, която кодира RT и протеаза от pol гена на НIV, получен от пациент, и с HIV-ДНК конструкт, от който последователността е делетирана. Трансфектираните клетки се култивират, така че да се създаде резерв от химерични вируси, след което се оценява тяхната фенотипна чувствителност към инхибитор на ензима, кодиран от pol гена на НIV, като в допълнение се определя стойност. След това се конструира набор от данни, състоящ се от стойността зачувствителност на химеричния вирус и съответната стойност за химеричния див тип щам НIV, повтаря се оценката на чувствителността за най-малко още два инхибитора и по такъв начин се конструират като цяло най-малко три такива набора от данни. Наборите от данни се представят в двудименсиална или тридименсиална графична форма, така че разликите между чувствителностите на химеричните и дивите типове за всеки един набор от данни да осигуряват визуално измерване на устойчивостта на химеричния резерв на третиране с въпросния инхибитор. След това се подбира оптималният инхибитор(и) въз основа на графичното представяне на измерената устойчивост.
BG102710A 1996-01-26 1998-08-20 Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове BG102710A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200175 1996-01-26
PCT/IB1997/000071 WO1997027480A1 (en) 1996-01-26 1997-01-24 Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains

Publications (1)

Publication Number Publication Date
BG102710A true BG102710A (bg) 1999-03-31

Family

ID=8223611

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102710A BG102710A (bg) 1996-01-26 1998-08-20 Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове

Country Status (21)

Country Link
US (3) US6221578B1 (bg)
EP (1) EP0877937B1 (bg)
KR (1) KR100495690B1 (bg)
CN (2) CN1991365A (bg)
AT (1) ATE217971T1 (bg)
AU (1) AU717755B2 (bg)
BG (1) BG102710A (bg)
BR (1) BR9707204A (bg)
CZ (1) CZ292899B6 (bg)
DE (1) DE69712731T2 (bg)
ES (1) ES2177922T3 (bg)
HU (1) HU226203B1 (bg)
IL (1) IL125442A (bg)
IS (1) IS4799A (bg)
NO (1) NO321329B1 (bg)
NZ (1) NZ325912A (bg)
PL (1) PL186473B1 (bg)
SK (1) SK283878B6 (bg)
TR (1) TR199801443T2 (bg)
WO (1) WO1997027480A1 (bg)
ZA (1) ZA97669B (bg)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US20030220276A1 (en) * 1995-05-16 2003-11-27 Opendra Narayan HIV vaccine and method of use
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20070010471A1 (en) * 1997-05-02 2007-01-11 Opendra Narayan HIV DNA vaccine
CA2298102A1 (en) * 1997-07-30 1999-02-11 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
NZ508834A (en) * 1998-05-26 2004-06-25 Virologic Inc Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
EP1109019A1 (en) * 1999-12-15 2001-06-20 BioStrands S.r.l. Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease
WO2001057245A2 (en) * 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
ATE526423T1 (de) 2000-04-18 2011-10-15 Virco Bvba Verfahren zum messen des medikamentenwiderstands gegen hcv
US6800463B1 (en) * 2000-04-20 2004-10-05 Virco Bvba Method for mutation detection in HIV-1 using pol sequencing
AU2001256318B8 (en) * 2000-04-20 2007-03-22 Virco Bvba Method for mutation detection in HIV using pol sequencing
US6582901B2 (en) * 2000-04-26 2003-06-24 Bruce K. Patterson Cell specific anti-viral drug susceptibility test using tagged permissive target cells
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
CA2411401A1 (en) * 2000-06-12 2001-12-20 Virologic, Inc. Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP4264256B2 (ja) * 2000-10-20 2009-05-13 ビルコ・ビーブイビーエイ 治療に対する耐性を予測するための生物学的カット−オフ値の確立
EP1356082A2 (en) * 2000-10-20 2003-10-29 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1283272B1 (en) * 2001-08-08 2013-11-13 Janssen R&D Ireland Methods and means for assessing HIV envelope inhibitor therapy
US6958211B2 (en) * 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
WO2003040390A2 (en) 2001-11-08 2003-05-15 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
DE60321466D1 (de) 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
CA2557790A1 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
AU2006323930B2 (en) 2005-12-07 2012-06-21 Janssen Sciences Ireland Uc Methods, plasmid vectors and primers for assessing HIV viral fitness
US20100009341A1 (en) * 2006-04-14 2010-01-14 Inky Paul Madeleine De Baere Methods and means for assessing hiv gag/protease inhibitor therapy
CA2688278A1 (en) 2007-05-25 2008-12-04 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
EP2342363B1 (en) * 2008-10-06 2015-06-10 Janssen Diagnostics BVBA Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6
US20120064514A1 (en) * 2009-05-12 2012-03-15 Virco Bvba Hiv-1-c resistance monitoring
CN107085093B (zh) * 2017-03-24 2019-06-21 西藏诺迪康药业股份有限公司 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875396A (en) 1973-11-12 1975-04-01 Illuminite Corp Illuminated clipboard
US4675147A (en) * 1983-04-06 1987-06-23 Westinghouse Electic Corp. Generating an integrated graphic display of the safety status of a complex process plant
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
IL94482A (en) 1989-05-25 2003-09-17 Univ Duke Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JPH05148202A (ja) * 1991-04-10 1993-06-15 Tsumura & Co 新規な化合物およびその医薬としての用途
AU4248593A (en) 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
KR100300932B1 (ko) 1992-07-06 2001-10-22 조이스 브린톤 리포터유전자에융합된세균의스트레스프로모터를이용하여독성을측정하는방법및진단키트
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CA2232086A1 (en) 1995-09-15 1997-04-03 Samir Chachoua Method for the identification and therapeutic use of disease-associated organisms, elements and forces
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5837464A (en) 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP0852626B1 (en) 1996-01-29 2002-04-03 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5945276A (en) 1996-04-10 1999-08-31 Signal Pharmaceuticals, Inc. Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression
US5939253A (en) 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
DE69804446T3 (de) 1997-04-07 2006-08-24 Bioimage A/S Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen
US6365347B1 (en) 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
WO1998059074A1 (en) 1997-06-23 1998-12-30 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
US5976813A (en) 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening

Also Published As

Publication number Publication date
HU226203B1 (en) 2008-06-30
NZ325912A (en) 1999-01-28
US6528251B2 (en) 2003-03-04
US20020042679A1 (en) 2002-04-11
NO983300L (no) 1998-09-25
US6221578B1 (en) 2001-04-24
EP0877937A1 (en) 1998-11-18
IL125442A0 (en) 1999-03-12
HUP9902618A3 (en) 2001-04-28
CZ292899B6 (cs) 2003-12-17
ZA97669B (en) 1998-06-25
IL125442A (en) 2002-03-10
PL328069A1 (en) 1999-01-04
KR19990082027A (ko) 1999-11-15
HUP9902618A2 (hu) 1999-12-28
AU1316897A (en) 1997-08-20
CZ233598A3 (cs) 1999-06-16
NO321329B1 (no) 2006-04-24
US20030152917A1 (en) 2003-08-14
SK283878B6 (sk) 2004-04-06
BR9707204A (pt) 1999-12-28
EP0877937B1 (en) 2002-05-22
SK100298A3 (en) 1999-02-11
WO1997027480A1 (en) 1997-07-31
TR199801443T2 (xx) 1998-10-21
ES2177922T3 (es) 2002-12-16
DE69712731T2 (de) 2003-02-06
ATE217971T1 (de) 2002-06-15
IS4799A (is) 1998-07-20
PL186473B1 (pl) 2004-01-30
NO983300D0 (no) 1998-07-16
CN1209875A (zh) 1999-03-03
DE69712731D1 (de) 2002-06-27
AU717755B2 (en) 2000-03-30
KR100495690B1 (ko) 2005-11-08
CN1991365A (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
BG102710A (bg) Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове
Ten Haaft et al. A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques
Berkhout et al. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains
Sawai et al. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef
Brighty et al. A cis-acting repressive sequence that overlaps the Rev-responsive element of human immunodeficiency virus type 1 regulates nuclear retention of env mRNAs independently of known splice signals.
Sakuragi et al. Possible role of dimerization in human immunodeficiency virus type 1 genome RNA packaging
Igarashi et al. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus
Tong-Starksen et al. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals.
Alexander et al. Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys
Wentz et al. A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production
Arya et al. Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging
Wang et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application
Protić et al. Enhancement of DNA repair capacity of mammalian cells by carcinogen treatment
Mwaengo et al. Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections
Groom et al. Rev regulates translation of human immunodeficiency virus type 1 RNAs
Paz et al. SRSF1 RNA recognition motifs are strong inhibitors of HIV-1 replication
Markine-Goriaynoff et al. The core 2 β-1, 6-N-acetylglucosaminyltransferase-mucin encoded by bovine herpesvirus 4 was acquired from an ancestor of the African buffalo
Carl et al. Partial “repair” of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection
Edmonson et al. Evolution of a simian immunodeficiency virus pathogen
Wang et al. Characterization of equine infectious anemia virus long terminal repeat quasispecies in vitro and in vivo
Sinclair et al. The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable
Johnston et al. Envelope gene-mediated neurovirulence in feline immunodeficiency virus infection: induction of matrix metalloproteinases and neuronal injury
Beer et al. Vaccine effect using a live attenuated nef-deficient simian immunodeficiency virus of African green monkeys in the absence of detectable vaccine virus replication in vivo
Renjifo et al. cis-acting elements in the U3 region of a simian immunodeficiency virus
Tokhanbigli et al. Intersecting SARS-CoV-2 spike mutations and global vaccine efficacy against COVID-19